EnPlusOne Biosciences, a biotechnology company utilizing the power of enzymes to deliver better RNA at scale, announced the appointment of Clare Murray, Ph.D., as Chief Executive Officer.
Dr. Murray has corporate strategy and business development expertise, having led multiple transactions with global pharmaceutical and innovative biotechnology companies. And her work signing strategic partnerships with CDMOs aligns with EnPlusOne’s roadmap to scale its manufacturing and deliver RNA therapeutics efficiently and precisely.
This appointment caps a time of increasing traction for EnPlusOne, which is actively partnering across the RNA therapeutic landscape to solve key manufacturing challenges, including achieving scale in siRNA, purity in gRNA synthesis, and novel RNA therapeutic design through enabling modifications. And EnPlusOne’s novel template-free, aqueous-based, and enzymatic RNA synthesis technology sets a new standard for sustainable, scalable RNA manufacturing and design.
Dr. Murray more recently served as Senior Vice President of Corporate Development and Operations at Life Edit Therapeutics, a gene editing discovery and development company she co-founded and scaled through acquisition by ElevateBio. And Dr. Murray also served as Head of Business Development and Strategy at ElevateBio. And her leadership experience spans early-stage innovation through late-stage commercial partnerships, including senior roles at AgBiome, Aptuit, SCYNEXIS, and Novartis. Dr. Murray has a B.Sc. in Chemistry, a Ph.D. in Synthetic Organic Chemistry from the University of Liverpool, and an MBA from the Fuqua School of Business at Duke University. She was also a Post-Doctoral Fellow at Washington University School of Medicine.
KEY QUOTES:
“We are thrilled to attract an extraordinary executive like Clare as EnPlusOne reaches an inflection point in its growth trajectory. Clare’s track record in company building and strategic partnerships makes her the ideal leader to guide us through our next phase of development as we accelerate commercialization of our ezRNA synthesis platform.”
- Steven Kasok, Chair of the EnPlusOne Board of Directors
“I’m excited to lead EnPlusOne at a time when the demand for high-quality RNA is surging. The team has built a truly differentiated technology that solves long-standing barriers to scale in siRNA and CRISPR therapeutics manufacturing. I look forward to expanding our commercial reach and helping realize the full potential of EnPlusOne’s platform.”
- Clare Murray
“Clare joins us at a pivotal moment as we scale our platform, advance high-purity guide RNA synthesis, and expand strategic collaborations across the RNA ecosystem to drive commercialization.”
- Dan Ahlstedt, co-founder and COO
“Clare’s leadership is exactly what EnPlusOne needs at this stage of growth. With our recent $10 million co-led financing with Breakout Ventures, we are confident she will be instrumental in bringing the company’s next-generation RNA solutions to market.”
- Paxton Major, board member and Managing Director at Northpond Ventures
